- cafead   Sep 13, 2024 at 11:13: AM
via Bright Minds Biosciences has announced the commencement of the Phase II BREAKTHROUGH clinical trial of BMB-101, targeting adult patients with classic absence epilepsy and developmental epileptic encephalopathy (DEE).
article source
article source